Vaxcyte Inc
PCVX56.150USD
+2.240+4.16%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
7.30BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Vaxcyte Inc Unternehmen
Vaxcyte Inc. is a clinical-stage vaccine innovation company. The Company is engaged in developing spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its pipeline includes VAX-31, a 31-valent PCV candidate advancing to a Phase III adult clinical program and being evaluated in a Phase II infant clinical program, which is being developed for the prevention of invasive pneumococcal disease (IPD) in adults and infants and is the broadest-spectrum pneumococcal conjugate vaccine (PCV) candidate in the clinic. VAX-24, the Company’s 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is being evaluated in a Phase II infant study. Its pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine candidate designed to prevent Shigella.
Vaxcyte Inc Informationen
BörsenkürzelPCVX
Name des UnternehmensVaxcyte Inc
IPO-datumJun 12, 2020
CEOPickering (Grant E)
Anzahl der mitarbeiter414
WertpapierartOrdinary Share
GeschäftsjahresendeJun 12
Addresse825 Industrial Road, Ste. 300
StadtSAN CARLOS
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl94070
Telefon16508370111
Websitehttps://vaxcyte.com/
BörsenkürzelPCVX
IPO-datumJun 12, 2020
CEOPickering (Grant E)
Führungskräfte von Vaxcyte Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Grant E. Pickering
Mr. Grant E. Pickering
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
558.46K
-100000.00%
Mr. James (Jim) Wassil
Mr. James (Jim) Wassil
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
27.26K
-7045.00%
Mr. Andrew L. Guggenhime
Mr. Andrew L. Guggenhime
President, Chief Financial Officer
President, Chief Financial Officer
13.74K
-61850.00%
Mr. Mikhail Eydelman, J.D.
Mr. Mikhail Eydelman, J.D.
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
12.60K
-5102.00%
Ms. Teri Loxam
Ms. Teri Loxam
Independent Director
Independent Director
8.67K
+3041.00%
Dr. Carlos V. Paya, M.D., Ph.D.
Dr. Carlos V. Paya, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
8.67K
+3041.00%
Mr. Jacks Lee
Mr. Jacks Lee
Independent Director
Independent Director
3.04K
+3041.00%
Mr. John P. Furey
Mr. John P. Furey
Independent Director
Independent Director
3.04K
+3041.00%
Dr. Olivier Brandicourt
Dr. Olivier Brandicourt
Independent Director
Independent Director
2.50K
+1357.00%
Ms. Halley E. Gilbert, J.D.
Ms. Halley E. Gilbert, J.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Grant E. Pickering
Mr. Grant E. Pickering
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
558.46K
-100000.00%
Mr. James (Jim) Wassil
Mr. James (Jim) Wassil
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
27.26K
-7045.00%
Mr. Andrew L. Guggenhime
Mr. Andrew L. Guggenhime
President, Chief Financial Officer
President, Chief Financial Officer
13.74K
-61850.00%
Mr. Mikhail Eydelman, J.D.
Mr. Mikhail Eydelman, J.D.
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
12.60K
-5102.00%
Ms. Teri Loxam
Ms. Teri Loxam
Independent Director
Independent Director
8.67K
+3041.00%
Dr. Carlos V. Paya, M.D., Ph.D.
Dr. Carlos V. Paya, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
8.67K
+3041.00%
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Sat, Nov 15
Aktualisiert: Sat, Nov 15
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Janus Henderson Investors
9.29%
The Vanguard Group, Inc.
8.63%
RA Capital Management, LP
8.48%
Fidelity Management & Research Company LLC
7.33%
BlackRock Institutional Trust Company, N.A.
5.95%
Andere
60.32%
Aktionäre
Aktionäre
Anteil
Janus Henderson Investors
9.29%
The Vanguard Group, Inc.
8.63%
RA Capital Management, LP
8.48%
Fidelity Management & Research Company LLC
7.33%
BlackRock Institutional Trust Company, N.A.
5.95%
Andere
60.32%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
40.80%
Investment Advisor/Hedge Fund
28.90%
Hedge Fund
17.96%
Venture Capital
10.55%
Research Firm
2.07%
Sovereign Wealth Fund
0.70%
Pension Fund
0.54%
Individual Investor
0.50%
Bank and Trust
0.43%
Institutionelle Beteiligung
Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
698
144.29M
102.33%
-18.18M
2025Q3
668
148.53M
114.41%
-14.14M
2025Q2
654
150.97M
116.29%
-1.23M
2025Q1
669
149.26M
115.73%
-5.52M
2024Q4
629
143.44M
111.44%
-3.61M
2024Q3
579
138.80M
114.99%
+5.28M
2024Q2
508
125.57M
113.86%
-5.08M
2024Q1
487
122.06M
113.01%
+8.05M
2023Q4
444
106.09M
111.72%
-6.02M
2023Q3
417
110.70M
121.97%
-7.51M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Janus Henderson Investors
13.10M
10.01%
-1.59M
-10.80%
Sep 30, 2025
The Vanguard Group, Inc.
12.29M
9.39%
+323.37K
+2.70%
Sep 30, 2025
RA Capital Management, LP
11.97M
9.14%
--
--
Sep 30, 2025
Fidelity Management & Research Company LLC
10.34M
7.9%
+289.69K
+2.88%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
8.39M
6.41%
-654.49K
-7.24%
Sep 30, 2025
T. Rowe Price Investment Management, Inc.
8.32M
6.35%
+2.31M
+38.56%
Sep 30, 2025
Wellington Management Company, LLP
5.03M
3.84%
+77.97K
+1.57%
Sep 30, 2025
State Street Investment Management (US)
4.79M
3.66%
-156.35K
-3.16%
Sep 30, 2025
D. E. Shaw & Co., L.P.
4.29M
3.28%
+1.20M
+38.93%
Sep 30, 2025
Paradigm BioCapital Advisors LP
3.78M
2.89%
+411.92K
+12.21%
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
Harbor Health Care ETF
4.32%
ALPS Medical Breakthroughs ETF
2.39%
State Street SPDR S&P Biotech ETF
1.65%
Direxion Daily S&P Biotech Bull 3X Shares
1.02%
Virtus LifeSci Biotech Clinical Trials ETF
0.89%
ProShares Ultra Nasdaq Biotechnology
0.58%
Invesco Nasdaq Biotechnology ETF
0.57%
iShares Biotechnology ETF
0.5%
JPMorgan Fundamental Data Science Small Core ETF
0.44%
iShares Russell 2000 Value ETF
0.34%
Mehr Anzeigen
Harbor Health Care ETF
Anteil4.32%
ALPS Medical Breakthroughs ETF
Anteil2.39%
State Street SPDR S&P Biotech ETF
Anteil1.65%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil1.02%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil0.89%
ProShares Ultra Nasdaq Biotechnology
Anteil0.58%
Invesco Nasdaq Biotechnology ETF
Anteil0.57%
iShares Biotechnology ETF
Anteil0.5%
JPMorgan Fundamental Data Science Small Core ETF
Anteil0.44%
iShares Russell 2000 Value ETF
Anteil0.34%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
